ArticlePloS one2026
Exploring the link between asprosin and glucose and lipid dysregulation in offspring of diabetic mothers in a rat model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal diabetes mellitus (DM) is a known risk factor for offspring metabolic dysfunction, predisposing them to DM later in life. While this association is established, the molecular mechanisms underlying the intergenerational transmission of DM risk are not fully understood. This study investigated the effects of in utero exposure to maternal DM on circulating levels of asprosin in offspring, aiming to clarify the potential role of asprosin in this pathological cascade. Twelve pregnant Wistar rats were randomized into two groups: a streptozotocin (STZ)-induced diabetic group (n = 6) and a non-diabetic control group (n = 6). DM was confirmed via blood glucose measurements (>250 mg/dL) 72 hours post-STZ administration. At 16 weeks postnatal, six male offspring per group were euthanized for plasma collection. Asprosin levels were measured using a commercial ELISA kit. Statistical analyses were performed to compare group means and determine the relationship between asprosin and variables. Maternal asprosin levels were significantly higher in the DM group compared to controls (330.70 ± 78.13 vs. 244.00 ± 21.54 pg/mL, P = 0.02). However, offspring of both groups showed comparable circulating asprosin concentrations (234.50 ± 10.60 vs 235.00 ± 7.23 pg/mL, P = 0.92). In contrast to diabetic mothers, in whom asprosin was significantly correlated with atherogenic lipid parameters and glucose homeostasis indices, no significant correlations were observed between asprosin and these parameters in offspring of either group. These preliminary findings suggest that asprosin may not be a critical mediator in the intergenerational transmission of diabetes-associated metabolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.